Aspira Women's Health Inc. announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA. The test is expected to be launched as a part of the Company's OvaSuite portfolio in collaboration with a consortium of world-renowned academic researchers under a previously announced licensing agreement. The poster, entitled: " Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model," highlighted data showing miRNA's potential to improve the diagnostic accuracy of non-invasive diagnostic tests.

With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus®? combines FDA-cleared products, Ova1®?

and Overa®?, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheckSM, Aspira's first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. These risks include, but are not limited to: ability to continue as a going concern; ability to comply with Nasdaq's continued listing requirements; impacts resulting from potential changes to coverage of Ova1 through the Medicare Administrative Carrier for Ova1; impacts resulting from or relating to the COVID-19 pandemic and actions taken to contain it; anticipated use of capital and its effects; ability to increase the volume of product sales; failures by third-party payers to reimburse for products and services or changes to reimbursement rates; ability to continue developing existing technologies and to develop, protect and promote proprietary technologies; plans to develop and perform laboratory developed tests; ability to comply with Food and Drug Administration ("FDA") regulations that relate to products and to obtain any FDA clearance or approval required to develop and commercialize medical devices; ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; ability to compete successfully; ability to obtain any regulatory approval required for future diagnostic products; or suppliers' ability to comply with FDA requirements for production, marketing and post-market monitoring of products; ability to maintain sufficient or acceptable supplies of immunoassay kits from suppliers; in the event that they succeed in commercializing their products outside the United States, the political, economic and other conditions affecting other countries; changes in healthcare policy; ability to comply with the additional laws and regulations that apply to us in connection with the operation of Aspira Labs; ability to use its net operating loss carryforwards; ability to use intellectual property; ability to use intellectual property, ability to use intellectual property; able to use its net operating loss carriedforwards; ability to use our net operating loss carryforward; ability to use intellectual property.